A model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) targeted individualized cancer chemotherapy

Drug Target Insights

Volumn 2009, Issue 4, 2009, Pages

  Begleiter, Asher ^a   El Gabalawy, Nadia ^a   Lange, Laurie ^a   Leith, Marsha K ^a   Guziec, Lynn J ^b   Guziec Jr , Frank S ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SOUTHWESTERN UNIVERSITY   (United States)

Author keywords

Benzoquinone mustard; Bioreductive agents; Individualized cancer chemotherapy; NQO1; Tumor targeting

Indexed keywords

BENZOQUINONE MUSTARD; BENZOQUINONE MUSTARD DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DAMAGE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 77953454398     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/dti.s1146     Document Type: Article

References (45)

1. Riley RJ., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992;43:1657-69.
2. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res. 1994;6:461-75.
3. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988;48:775-8.
4. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 1993;12:73-82.
5. Rockwell S, Sartorelli AC, Tomasz M, Kennedy KA. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev. 1993;12:165-76.
6. Rauth AM, Marshall RS, Kuehl BL. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev. 1993;12:153-64.
7. Begleiter A. Clinical applications of quinone alkylating agents. Frontiers Bioscience. 2000;5:e153-71.
8. Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat. Res. 1988;116:100-13.
9. Chamberlain MC, Prados MD, Silver P, Levin VA. A phase I/II study of 24 hour intravenous AZQ. in recurrent primary brain tumors. J Neurooncol. 1988;6:319-23.
10. Schellens JHM, Planting AST, Van Acker BAC, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994;86:906-12.
11. Dirix LY, Tonnesen F, Cassidy J, et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. Eur J Cancer [A]. 1996;32A:2019-22.
12. Senan S, Rampling R, Graham MA, et al. Phase I and pharmacokinetic study of tirapazamine (SR. 4233) administered every three weeks. Clin Cancer Res. 1997;3:31-8.
13. Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study. Int J Radiat Oncol Biol Phys. 1998;42:811-5.
14. Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin. Cancer Res. 1998;4:3083-8.
15. Loadman PM, Phillips RM, Lim LE, Bibby MC. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Biochem Pharmacol. 2000;59:831-7.
16. Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol. 2002;137:701-9.
17. Jaffar M, Phillips RM, Williams KJ, et al. 3-Substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro. Biochem Pharmacol. 2003;66:1199-206.
18. Hortobagyi GN. Mitomycin: Its evolving role in the treatment of breast cancer. Oncology (Basel). 1993;50 Suppl 1:1-8.
19. Digby T, Leith MK, Thliveris JA, Begleiter A. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo. Cancer Chemother Pharmacol. 2005;56:307-16.
20. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev. 1993;12:83-101.
21. Pan SS, Andrews PA, Glover CJ, Bachur NR. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem. 1984; 259:959-66.
22. Jaiswal AK. Human NAD(P)H: quinone oxidoreductase (NQO-1) gene structure and induction by dioxin. Biochemistry. 1991;30:10647-53.
23. Jaiswal AK, Burnett P, Adesnick M, McBride OW. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H: quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry. 1990;29:1899-906.
24. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 1993;12:103-17.
25. Winski SL, Koutalos Y., Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. 2002;62:1420-4.
26. Schlager JJ. and Powis G. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45:403-9.
27. Smitskamp-Wilms EG, Giaccone G, Pinedo HM, Van der Laan BFAM, Peters GJ. DT-diaphorase activity in normal and neoplastic human tissues; An indicator for sensitivity to bioreductive agents? Br J Cancer. 1995;72:917-21.
28. Begleiter A, Leith MK, Curphey TJ., Doherty GP. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res. 1997;9:371-82.
29. Twerdok LE, Rembish SJ, Trush MA. Induction of quinone reductase and glutathione in bone marrow cells by 1,2-dithiole-3-thione: effect on hydroquinone-induced cytotoxicity. Toxicol Applied Pharmacol. 1992;112:273-81.
30. Begleiter A, Robotham E, Lacey G, Leith MK. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett. 1989; 45:173-6.
31. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990; 50:7483-9.
32. Pan S, Akman SA, Forrest GL, Hipsher C, Johnson R. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfi romycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother Pharmacol. 1992;31:23-31.
33. Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J, Ross D. Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumour quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol. 1995;48:499-504.
34. Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 1994;29:295-9.
35. Winski SL, Swann E, Hargreaves RHJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol.. 2001;61:1509-16.
36. Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small lung carcinoma: relationship to the response of lung xenografts to mitomycin C. Cancer Res. 1992;52:4752-7.
37. Marshall RS, Patterson MC, Rauth AM. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis. 1991;12:1175-80.
38. Dusre L, Covey JM, Collins C, Sinha BK. DNA damage, cytotoxicity and free radical formation by mitomycin C in human cells. Chem Biol Interac. 1989;71:63-78.
39. Begleiter A and Leith MK. Activity of quinone alkylating agents in quinone-resistant cells. Cancer Res. 1990;50:2872-6.
40. Begleiter A, Lee K, Israels LG, Mowat MRA, Johnston JB. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia. 1994;8(Suppl 1):S103-6.
41. Fourie J, Oleschuk C, Guziec F Jr, et al. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother Pharmacol. 2002;49:101-10.
42. Fourie J, Guziec F Jr, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A. Structure-activity study of benzoquinone bioreductive alkylating agents: Effects on DT-diaphorase mediated DNA cross-link and strand break formation and relation to mechanisms of cytotoxicity. Cancer Chemother Pharmacol. 2004;53:191-203.
43. Doherty GP, Leith MK, Wang X, Curphey TJ, Begleiter A. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on antitumour activity of bioreductive agents. Br J Cancer. 1998;77:1241-52.
44. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia. 1994;8(Suppl 1):S140-3.
45. Kirkpatrick DL, Duke M, Goh TS. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leuk Res. 1990;14:459-66.